Trends in Use and Perceptions About Triplet Chemotherapy Plus Bevacizumab for Metastatic Colorectal Cancer

IMPORTANCE: Triplet chemotherapy with fluorouracil, folinic acid, oxaliplatin, and irinotecan plus bevacizumab (FOLFOXIRI-B) is an effective first-line treatment option for patients with metastatic colorectal cancer (mCRC). However, the degree of implementation of FOLFOXIRI-B in daily practice is un...

Descripción completa

Detalles Bibliográficos
Autores principales: van Nassau, Sietske C., Bond, Marinde J., Scheerman, Ilva, van Breeschoten, Jesper, Kessels, Rob, Valkenburg-van Iersel, Liselot B., Verheul, Henk M., Buffart, Tineke E., Mekenkamp, Leonie J., Lemmens, Valery E., Koopman, Miriam, Bol, Guus M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8433607/
https://www.ncbi.nlm.nih.gov/pubmed/34505885
http://dx.doi.org/10.1001/jamanetworkopen.2021.24766

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8433607/
https://www.ncbi.nlm.nih.gov/pubmed/34505885
http://dx.doi.org/10.1001/jamanetworkopen.2021.24766

Ejemplares similares